FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FDA approves Genentech drug aimed at subset of breast cancer patients
The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential ...
Business Wire6d
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebiâ„¢ (inavolisib), in ...
Genentech Itovebi Gets FDA Approval for Treating Breast Cancer
The approval is for Itovebi in combination with palbociclib and fulvestrant and for treating adults a certain locally advanced or metastatic breast cancer, as detected by an FDA-approved test, ...
FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation
Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved Itovebi (inavolisib), in ...
The Pharma Letter5d
FDA approves Genentech’s Itovebi for PIK3CA-mutated mBC
The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...
Stockhouse6d
FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
– Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Managed Healthcare Executive5d
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...